(Formerly the Office of the Chief Scientist and MATIMOP)
 
SEARCH
 
 
 

Improdia: Reporting on the Status of the Immune System

The international collaboration between Improdia and SBH Sciences provided funding, significant exposure, and an opportunity to break into the American market.

Improdia has discovered two biomarkers – proteins which exist within white blood cells and are able to report the status of a body’s immune system at any given moment, based on a simple blood test. This check-up of the immune system helps in combating chronic illnesses, such as cancer, Crohn’s Disease, AIDS and more, and provides indication of the patient’s condition – whether it is improving or deteriorating. The company took its first steps by launching an academic research project at the Hebrew University in 2003, in the laboratory of Professor Michal Beniash. Improdia became a commercial company in early 2012. Currently, Improdia conducts the advanced stages of development and intends to aid in the treatment of several diseases, such as cancer and diabetes. In its first stage, the development may revolutionize the field of immune system disorders.

 

“We are occupying a non-existent niche,” says Tuvia Sofinzon, Company CEO. “None of the currently available methods for testing the immune system provide a complete answer.”

 

Support from the Government – During the Most Critical Phase

 

Improdia’s collaboration with the American company, SBH Sciences Inc., began in early 2012, after the Chief Scientist’s Office and MATIMOP issued a call for proposals for the first bilateral collaboration program with the American state of Massachusetts. The American company acts as a manufacturer of the blood testing kit developed by Improdia. “Each of the collaborating companies received funding from its respective state,” says Sofinzon. “The grant from the Chief Scientist is given during the most critical phase of development.” Beyond the monetary support, the “seal of approval” provided by the Chief Scientist and its American equivalent also benefited both companies.

 

“We were exposed to new markets and were featured at conventions and in several American television shows. This exposure is incredibly valuable for us.”

 

Another significant added value, adds Sofinzon enthusiastically, is access to investors and the opportunity to operate in one of the world’s largest markets.

 

“A small company, lacking the funds, the man power, or the technological resources, has no chance to reach international markets without an international partner. This collaboration has undoubtedly reinforced our company in a major way.”